Clarus’ proprietary Virus Like Particle is fully developed and successfully tested in multiple pre-clinical studies. Based on these results, and its applicability across multiple segments of the life sciences industry, we believe CBI-3A provides a unique solution to existing vaccine market challenges and future of immunotherapy. In addition, our business development strategy is designed to target key differences in entry to applicable market segments, reducing risk and accelerating  positive cash flow.

Please contact us if you would like to know more about this unique and compelling investment opportunity or believe this technology with your antigen could show promising results.

After you complete the form you will be able to download key investment documentation – our Investor Presentation and Investment Questionnaire.